mTOR signaling in glioblastoma: lessons learned from bench to bedside

Phosphatidyl-inositol-3 kinases (PI3Ks) constitute a family of intracellular lipid kinases that are frequently hyperactivated in glioblastoma. The PI3K complex links growth factor signaling with cellular proliferation, differentiation, metabolism, and survival. Mammalian target of rapamycin (mTOR) acts both as a downstream effector and upstream regulator of PI3K, thus highlighting its importance in glioblastoma. This review highlights laboratory and clinical evidence of mTOR's role in glioblastoma. Mechanisms of escape from mTOR inhibition are also discussed, as well as future clinical strategies of mTOR inhibition.

• Publication year

  2010

• Venue

  Neuro-Oncology

• Publication date

  2010-05-14

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1093/neuonc/noq052PMID 20472883PMCID 2940679
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• When speed matters: Leukemogenic transformation by MLL fusion proteins

  2010cited by this paper
• AMPK: A metabolic checkpoint that regulates the growth of EGFR activated glioblastomas

  2010influential reference
• A Drosophila Model for EGFR-Ras and PI3K-Dependent Human Glioma

  2009cited by this paper
• Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis.

  2009cited by this paper
• Cell type specificity of PI3K signaling in Pdk1- and Pten-deficient brains.

  2009cited by this paper
• Role of a Novel PH-Kinase Domain Interface in PKB/Akt Regulation: Structural Mechanism for Allosteric Inhibition

  2009cited by this paper
• EGFR Signals to mTOR Through PKC and Independently of Akt in Glioma

  2009cited by this paper
• DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival.

  2009cited by this paper
• Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation.

  2009cited by this paper
• PI3K Signaling in Glioma—Animal Models and Therapeutic Challenges

  2009cited by this paper
• The Pharmacology of mTOR Inhibition

  2009influential reference
• Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma

  2009cited by this paper
• EGFR Signaling Through an Akt-SREBP-1–Dependent, Rapamycin-Resistant Pathway Sensitizes Glioblastomas to Antilipogenic Therapy

  2009cited by this paper
• The LKB1–AMPK pathway: metabolism and growth control in tumour suppression

  2009cited by this paper
• PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR.

  2009cited by this paper
• Development of a novel mouse glioma model using lentiviral vectors

  2009cited by this paper
• An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1*

  2009cited by this paper
• LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition

  2009cited by this paper
• The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis

  2009cited by this paper
• A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM)

  2009cited by this paper
• Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition

  2009cited by this paper
• Development of a Real-time RT-PCR Assay for Detecting EGFRvIII in Glioblastoma Samples

  2008cited by this paper
• Comprehensive genomic characterization defines human glioblastoma genes and core pathways

  2008cited by this paper
• Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma

  2008cited by this paper
• An Integrated Genomic Analysis of Human Glioblastoma Multiforme

  2008cited by this paper
• Amino acids activate mTOR complex 1 via Ca2+/CaM signaling to hVps34.

  2008cited by this paper
• AMPK phosphorylation of raptor mediates a metabolic checkpoint.

  2008cited by this paper
• Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer.

  2008cited by this paper
• S6K1 plays a key role in glial transformation.

  2008cited by this paper
• Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

  2008cited by this paper
• Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel

  2007cited by this paper
• Malignant astrocytic glioma: genetics, biology, and paths to treatment.

  2007cited by this paper
• Coactivation of Receptor Tyrosine Kinases Affects the Response of Tumor Cells to Targeted Therapies

  2007cited by this paper
• New insight into BRAF mutations in cancer.

  2007cited by this paper
• Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma

  2007cited by this paper
• Intramolecular and Intermolecular Interactions of Protein Kinase B Define Its Activation In Vivo

  2007cited by this paper
• A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma.

  2007cited by this paper
• Regulation of Endothelial Cell Cycle by Laminar Versus Oscillatory Flow: Distinct Modes of Interactions of AMP-Activated Protein Kinase and Akt Pathways

  2007cited by this paper
• mTORC2 activity is elevated in gliomas and promotes growth and cell motility via overexpression of rictor.

  2007cited by this paper
• PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR.

  2007cited by this paper
• Phase 1 Trial of Gefitinib Plus Sirolimus in Adults with Recurrent Malignant Glioma

  2006cited by this paper
• Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells.

  2006cited by this paper
• mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt.

  2006cited by this paper
• Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells

  2006cited by this paper
• mTOR and cancer: insights into a complex relationship

  2006cited by this paper
• mTOR and cancer therapy

  2006cited by this paper
• The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism

  2006influential reference
• Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas

  2006cited by this paper
• A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma.

  2006cited by this paper
• Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

  2005cited by this paper
• Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme

  2005cited by this paper
• mTOR promotes survival and astrocytic characteristics induced by Pten/AKT signaling in glioblastoma.

  2005cited by this paper
• Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex

  2005cited by this paper
• Somatic induction of Pten loss in a preclinical astrocytoma model reveals major roles in disease progression and avenues for target discovery and validation.

  2005cited by this paper
• Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study.

  2005cited by this paper
• Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib.

  2005cited by this paper
• Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

  2005cited by this paper
• Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy

  2004cited by this paper
• mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways

  2004cited by this paper
• Oligodendrogliomas result from the expression of an activated mutant epidermal growth factor receptor in a RAS transgenic mouse astrocytoma model.

  2003cited by this paper
• Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors.

  2003cited by this paper
• Genetic determinants of malignancy in a mouse model for oligodendroglioma.

  2003cited by this paper
• Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo.

  2003cited by this paper
• TSC2 mediates cellular energy response to control cell growth and survival.

  2003cited by this paper
• Targeting RAS signalling pathways in cancer therapy

  2003cited by this paper
• Astrocyte inactivation of the pRb pathway predisposes mice to malignant astrocytoma development that is accelerated by PTEN mutation.

  2002cited by this paper
• Mutations of the BRAF gene in human cancer

  2002cited by this paper
• Dysregulation of PTEN and protein kinase B is associated with glioma histology and patient survival.

  2002cited by this paper
• Mutations to CCI-779 PTEN Enhanced Sensitivity of Multiple Myeloma Cells Containing Updated Version

  2002cited by this paper
• Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis.

  2002cited by this paper
• The phosphatidylinositol 3-Kinase–AKT pathway in human cancer

  2002cited by this paper
• Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy.

  2002cited by this paper
• Gliomagenesis: genetic alterations and mouse models

  2001cited by this paper
• An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/− mice

  2001cited by this paper
• mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer.

  2001cited by this paper
• Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR

  2001cited by this paper
• Akt pathway activation converts anaplastic astrocytoma to glioblastoma multiforme in a human astrocyte model of glioma.

  2001cited by this paper
• The Enhanced Tumorigenic Activity of a Mutant Epidermal Growth Factor Receptor Common in Human Cancers Is Mediated by Threshold Levels of Constitutive Tyrosine Phosphorylation and Unattenuated Signaling*

  1997cited by this paper
• Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII.

  1997cited by this paper
• Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha.

  1997cited by this paper
• Differential Modulation of Mitogen-activated Protein (MAP) Kinase/Extracellular Signal-related Kinase Kinase and MAP Kinase Activities by a Mutant Epidermal Growth Factor Receptor (*)

  1995cited by this paper

• The functional imperative in high-grade glioma

  2026influential citation
• Repeat resection for recurrent glioblastoma – does timing matter?

  2026cites this paper
• RSK1 and RSK2 modulate the translatome of glioblastoma cells in an isoform-specific and mTORC1 independent manner

  2025cites this paper
• Identification of a ceRNA Network Regulating Malignant Transformation of Isocitrate Dehydrogenase Mutant Astrocytoma: An Integrated Bioinformatics Study.

  2025cites this paper
• A novel approach to glioblastoma multiforme treatment using modulation of key pathways by naturally occurring small molecules

  2025cites this paper
• Targeting EGFR and PI3K/mTOR pathways in glioblastoma: innovative therapeutic approaches

  2025cites this paper
• Isobolographic interactions of cannabidiol and AM 1172 with cisplatin in human neuroblastoma and glioblastoma cell lines: an in vitro study.

  2025cites this paper
• Targeting chaperone-mediated autophagy inhibits properties of glioblastoma stem cells and restores anti-tumor immunity

  2025cites this paper
• Cut the fat: targeting cholesterol and lipid metabolism in glioblastoma

  2025cites this paper
• The Role of mTOR Signaling in Tumor-Induced Alterations to Neuronal Function in Diffusely Infiltrating Glioma

  2025cites this paper
• Glioma-induced alterations in excitatory neurons are reversed by mTOR inhibition.

  2025cites this paper
• Leveraging Medulloblastoma Clonal Dynamics to Overcome Treatment Resistance.

  2025cites this paper
• The hidden architects of glioblastoma multiforme: Glioma stem cells

  2024cites this paper
• Recurrent Glioblastoma—Molecular Underpinnings and Evolving Treatment Paradigms

  2024cites this paper
• High-dimensional covariance regression with application to co-expression QTL detection

  2024cites this paper
• Exploring glioma heterogeneity through omics networks: from gene network discovery to causal insights and patient stratification

  2024cites this paper
• Noninvasive prediction of CCL2 expression level in high‐grade glioma patients

  2024cites this paper
• Breed-Associated Differences in Differential Gene Expression Following Immunotherapy-Based Treatment of Canine High-Grade Glioma

  2024cites this paper
• Glioma-Induced Alterations in Excitatory Neurons are Reversed by mTOR Inhibition

  2024cites this paper
• PIM Kinase Inhibitors as Novel Promising Therapeutic Scaffolds in Cancer Therapy.

  2024cites this paper
• Dual targeting of histone deacetylases and MYC as potential treatment strategy for H3-K27M pediatric gliomas

  2024cites this paper
• Repeat surgery of recurrent glioma for molecularly informed treatment in the age of precision oncology: A risk–benefit analysis

  2024cites this paper
• Novel Natural Inhibitors for Glioblastoma by Targeting Epidermal Growth Factor Receptor and Phosphoinositide 3-kinase.

  2024cites this paper
• PiDeeL: metabolic pathway-informed deep learning model for survival analysis and pathological classification of gliomas

  2023cites this paper
• Emerging roles of the cellular prion protein (PrPC) and 37/67 kDa laminin receptor (RPSA) interaction in cancer biology

  2023cites this paper
• The Impact of ROS and NGF in the Gliomagenesis and their Emerging Implications in the Glioma Treatment.

  2023cites this paper
• Signaling pathways in brain tumors and therapeutic interventions

  2023cites this paper
• m6A-modification of cyclin D1 and c-myc IRESs in glioblastoma controls ITAF activity and resistance to mTOR inhibition.

  2023cites this paper
• Target-Based Anticancer Indole Derivatives for the Development of Anti-Glioblastoma Agents

  2023cites this paper
• PiDeeL: Pathway-Informed Deep Learning Model for Survival Analysis and Pathological Classification of Gliomas

  2023cites this paper
• Dual Targeting of EGFR and MTOR Pathways Inhibits Glioblastoma Growth by Modulating the Tumor Microenvironment

  2023cites this paper
• Brain Tumors: Development, Drug Resistance, and Sensitization – An Epigenetic Approach

  2023cites this paper
• Spreading of Alpha Synuclein from Glioblastoma Cells towards Astrocytes Correlates with Stem-like Properties

  2022cites this paper
• EGFR suppresses p53 function by promoting p53 binding to DNA-PKcs: a noncanonical regulatory axis between EGFR and wild-type p53 in glioblastoma

  2022cites this paper
• Small molecule-mediated disruption of ribosome biogenesis synergizes with FGFR inhibitors to suppress glioma cell growth

  2022cites this paper
• Wnt and PI3K/Akt/mTOR Survival Pathways as Therapeutic Targets in Glioblastoma

  2022cites this paper
• Glioblastoma‐derived extracellular vesicle subpopulations following 5‐aminolevulinic acid treatment bear diagnostic implications

  2022cites this paper
• Phosphoproteomic Analysis Defines BABAM1 as mTORC2 Downstream Effector Promoting DNA Damage Response in Glioblastoma Cells

  2022cites this paper
• ROS-Induced Cancers

  2022cites this paper
• The DNA Double-Strand Break Repair in Glioma: Molecular Players and Therapeutic Strategies

  2022cites this paper
• Molecular Pathways and Genomic Landscape of Glioblastoma Stem Cells: Opportunities for Targeted Therapy

  2022cites this paper
• Autophagy mediated lipid catabolism facilitates glioma progression to overcome bioenergetic crisis

  2021cites this paper
• Single-cell profiling of D-2-hydroxyglutarate using surface-immobilized resazurin analogs.

  2021cites this paper
• Therapeutic strategies of glioblastoma (GBM): The current advances in the molecular targets and bioactive small molecule compounds

  2021cites this paper
• A Preclinical Investigation of GBM-N019 as a Potential Inhibitor of Glioblastoma via Exosomal mTOR/CDK6/STAT3 Signaling

  2021cites this paper
• D-2-Hydroxyglutarate in Glioma Biology

  2021cites this paper
• Reactive Species and ER-Mitochondrial Performance for Glioblastoma Multiforme Treatment Strategy

  2021cites this paper
• STAT3 suppresses the AMPKα/ULK1‐dependent induction of autophagy in glioblastoma cells

  2021cites this paper
• Knockdown of Annexin-A1 Inhibits Growth, Migration and Invasion of Glioma Cells by Suppressing the PI3K/Akt Signaling Pathway

  2021cites this paper
• Role of glioblastoma stem cells in cancer therapeutic resistance: a perspective on antineoplastic agents from natural sources and chemical derivatives

  2021cites this paper
• Insights into Molecular Mediators of Oxidative Stress and Inflammation in Glioblastoma Multiforme

  2021cites this paper
• Novel Repositioning Therapy for Drug-Resistant Glioblastoma: In Vivo Validation Study of Clindamycin Treatment Targeting the mTOR Pathway and Combination Therapy with Temozolomide

  2021cites this paper
• Genome-wide translation patterns in gliomas: An integrative view.

  2020cites this paper
• Targeting protein kinases for anti-glioma treatment.

  2020cites this paper
• Brain-restricted mTOR inhibition with binary pharmacology

  2020cites this paper
• PODNL1 promotes cell proliferation and migration in glioma via regulating Akt/mTOR pathway

  2020cites this paper
• An Experimentally Defined Hypoxia Gene Signature in Glioblastoma and Its Modulation by Metformin

  2020cites this paper
• In vitro effect of ionizing radiation on primary glioblastoma cells as a basis for multitarget therapy

  2020cites this paper
• CFTR promotes malignant glioma development via up‐regulation of Akt/Bcl2‐mediated anti‐apoptosis pathway

  2020cites this paper
• The Autophagy Status of Cancer Stem Cells in Gliobastoma Multiforme: From Cancer Promotion to Therapeutic Strategies

  2019cites this paper
• Menthol-modified BSA nanoparticles for glioma targeting therapy using an energy restriction strategy

  2019cites this paper
• Tissues Harvested Using an Automated Surgical Approach Confirm Molecular Heterogeneity of Glioblastoma and Enhance Specimen's Translational Research Value

  2019cites this paper
• mTOR protein

  2019cites this paper
• Glioblastoma diagnostics and prognostic biomarkers: Current status in medicine and exosome derivation

  2019cites this paper
• RETRACTED: The Brain Penetrating and Dual TORC1/TORC2 Inhibitor, RES529, Elicits Anti-Glioma Activity and Enhances the Therapeutic Effects of Anti-Angiogenetic Compounds in Preclinical Murine Models

  2019cites this paper
• Aberrant expression of RSK1 characterizes high‐grade gliomas with immune infiltration

  2019cites this paper
• Discovery and Therapeutic Exploitation of Mechanisms of Resistance to MET Inhibitors in Glioblastoma

  2018cites this paper
• A molecular cascade modulates MAP1B and confers resistance to mTOR inhibition in human glioblastoma

  2018cites this paper
• Repurposing of mTOR Complex Inhibitors Attenuates MCL-1 and Sensitizes to PARP Inhibition

  2018cites this paper
• The Intracellular Cleavage Product of the NG2 Proteoglycan Modulates Translation and Cell-Cycle Kinetics via Effects on mTORC1/FMRP Signaling

  2018cites this paper
• mTOR-Related Brain Dysfunctions in Neuropsychiatric Disorders

  2018cites this paper
• Subtype-specific signaling pathways and genomic aberrations associated with prognosis of glioblastoma

  2018cites this paper
• Mammalian Sterile20-like Kinases: Signalings and Roles in Central Nervous System

  2018cites this paper
• A new diffusely infiltrating glioma mouse model reveals neuronal alterations in the brain tumor microenvironment

  2018cites this paper
• Targeting mTOR in Glioblastoma: Rationale and Preclinical/Clinical Evidence

  2018cites this paper
• Inhibition of mTORC1 in pediatric low-grade glioma depletes glutathione and therapeutically synergizes with carboplatin

  2018cites this paper
• Fenofibrate inhibits mTOR-p70S6K signaling and simultaneously induces cell death in human prostate cancer cells.

  2018cites this paper
• Recent Advances in Targeted Therapy for Glioma.

  2017cites this paper
• Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma

  2017cites this paper
• Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.

  2017cites this paper
• Amplification of the EGFR gene can be maintained and modulated by variation of EGF concentrations in in vitro models of glioblastoma multiforme

  2017cites this paper
• Evaluation of Akt and RICTOR Expression Levels in Astrocytomas of All Grades

  2017influential citation
• Autophagy suppression sensitizes glioma cells to IMP dehydrogenase inhibition‐induced apoptotic death

  2017cites this paper
• Exploring the key genes and signaling transduction pathways related to the survival time of glioblastoma multiforme patients by a novel survival analysis model

  2017cites this paper
• 13 Genetics and Biology of Glioblastoma Multiforme

  2017cites this paper
• In-vitro evaluation of MPA-loaded electrospun coaxial fiber membranes for local treatment of glioblastoma tumor cells

  2017cites this paper
• Mammalian target of rapamycin inhibitors, temsirolimus and torin 1, attenuate stemness-associated properties and expression of mesenchymal markers promoted by phorbol-myristate-acetate and oncostatin-M in glioblastoma cells

  2017cites this paper
• MFN2 suppresses cancer progression through inhibition of mTORC2/Akt signaling

  2017cites this paper
• Rewiring the spinal cord: Direct and indirect strategies.

  2017cites this paper
• mTOR-Dependent Cell Proliferation in the Brain

  2017cites this paper
• mTORC2 regulates hedgehog pathway activity by promoting stability to Gli2 protein and its nuclear translocation

  2017cites this paper
• Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma

  2017cites this paper
• Targeting Aberrant Signaling Pathways

  2017cites this paper
• Recent Advances for Targeted Therapies in Glioblastoma

  2017cites this paper
• Metabolic Reprogramming in Glioma

  2017influential citation
• Preclinical analysis of MTOR complex 1/2 inhibition in diffuse intrinsic pontine glioma

  2017cites this paper
• The emerging role of m-TOR up-regulation in brain Astrocytoma.

  2016cites this paper
• The mTOR signalling cascade: paving new roads to cure neurological disease

  2016cites this paper
• Blocking the Nogo-A Signaling Pathway to Promote Regeneration and Plasticity After Spinal Cord Injury and Stroke

  2016cites this paper
• Silencing of PROS1 induces apoptosis and inhibits migration and invasion of glioblastoma multiforme cells.

  2016cites this paper